Nacuity announces positive clinical results: oral treatment NPI-001 reduces photoreceptor loss by over 50% in Usher syndrome patientsThursday 11th September. A major step forward…

Save Sight Now Europe is proud to fund a cutting-edge research program led by Prof. Elvir Becirovic and his team at the University of…

Understanding MYO7A to Advance USH1B Therapies The goal of this project is twofold: 1. To gain a deeper understanding of the molecular causes of…

Retina Murcia Association launches with its Research Group on Rare Visual Diseases (GISERV) the first Report on Rare Visual Diseases. Spain has published its…

Save Sight Now Europe attended Euretina’24 in Barcelona from 19-22nd of September It was an honor to represent Usher Syndrome at the EURETINA 2024…

Save Sight Now Europe joined the team at L’Institut de la Vision, Paris, to collaborate and help accelerate treatments. Our recent visit to L’Institut…

AAVantgarde Announces LUCE-1 Trial for Usher Syndrome Type 1B and First Patient Dosed AAVantgarde has unveiled the design of its innovative LUCE-1 trial for…

Championing Usher Syndrome: Highlights from RIWC24 in Dublin We are thrilled to share our experience at the Retina International World Congress 2024 (RIWC24) in…

Save Sight Now Europe has been at ARVO 2024 to Champion Advances in Retinal Disease Treatments From 4th to 10th May, Save Sight Now…

AAVantgarde Bio Unveils Innovative LUCE-1 Clinical Trial Design (for USH1B) at Gene Therapy Summit Seattle, May 3, 2024 — AAVantgarde Bio, an Italian-based biotechnology…

First gene therapy treatment for a hereditary form of deafness in the USA The Children’s Hospital of Philadelphia successfully administered the first gene therapy…

SSNEU is collaborating with breakthrough research on gene editing for USH1B that offers hope for patients In a significant stride toward combating Usher Syndrome…

Incredible experience at the Save Sight Now Europe | Foundation Usher Syndrome presentation event last Tuesday 7th November 2023, at the Old Estrella Damm…

Save Sight Now Europe has awarded its first grant to the University of Wisconsin-Madison to fund research on gene editing in retinal degeneration. The…

Uni-Rare is a Natural History Study of vision loss progression. It is a critical and necessary step in supporting the approval of upcoming clinical…

Researchers now have a model for testing gene therapy as a treatment for a leading cause of blindness-deafness. Save Sight Now has helped fund this…

It will be for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes. It will include USH1B and Save Sight Now helped…

We are starting a difficult journey, but one that comes from within, from our need to push and support, and from our will to…

Defining Characteristics & Research Significance Being born severe to profoundly deaf or gradually losing hearing, losing vision starting in infancy or later in adolescence,…

Save Sight Now is funding groundbreaking research on Usher syndrome. For the last two years, Save Sight Now has supported a project that is…